Concentration–QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation

Concentration‐QTcF data obtained from two phase I studies in healthy volunteers treated with a novel phosphodiesterase‐4 inhibitor currently under development for the treatment of chronic obstructive pulmonary disease were analyzed by means of mixed‐effects modeling. A simple linear mixed‐effects mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jolling, Koen, Äbelö, Angela, Luyckx, Nicolas, Nandeuil, Marie‐Anna, Govoni, Mirco, Cella, Massimo, Lindauer, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656937/
https://www.ncbi.nlm.nih.gov/pubmed/31077576
http://dx.doi.org/10.1002/psp4.12405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656937/
https://www.ncbi.nlm.nih.gov/pubmed/31077576
http://dx.doi.org/10.1002/psp4.12405

Ejemplares similares